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1909), thus initiating a century of contentious debate
over immunologic control of neoplasia. Fifty years later,
The last fifteen years have seen a reemergence of as immunologists gained an enhanced understanding
interest in cancer immunosurveillance and a broaden- of transplantation and tumor immunobiology and immu-
ing of this concept into one termed cancer immuno- nogenetics, F. Macfarlane Burnet and Lewis Thomas
editing. The latter, supported by strong experimental revisited the topic of natural immune protection against
data derived from murine tumor models and provoca- cancer. Burnet’s thinking was shaped by a consideration
tive correlative data obtained by studying human can- of immune tolerance; he believed that tumor cell-spe-
cer, holds that the immune system not only protects cific neo-antigens could provoke an effective immuno-
the host against development of primary nonviral can- logic reaction that would eliminate developing cancers
cers but also sculpts tumor immunogenicity. Cancer (Burnet, 1957, 1964, 1971). Alternatively, Thomas’s early
immunoediting is a process consisting of three phases: view was evolutionary in nature; he theorized that com-
elimination (i.e., cancer immunosurveillance), equilib- plex long-lived organisms must possess mechanisms
rium, and escape. Herein, we summarize the data sup- to protect against neoplastic disease similar to those
porting the existence of each of the three cancer im- mediating homograft rejection (Thomas, 1959). With the
munoediting phases. The full understanding of the functional demonstration of mouse tumor-specific anti-
immunobiology of cancer immunosurveillance and im- gens supporting the ideas of Ehrlich, Burnet, and
munoediting will hopefully stimulate development of Thomas (Old and Boyse, 1964), the cancer immunosur-
more effective immunotherapeutic approaches to veillance hypothesis, which stated that sentinel thymus-
control and/or eliminate human cancers. dependent cells of the body constantly surveyed host
tissues for nascently transformed cells (Burnet, 1970),
gained recognition. Despite subsequent challenges to
Comments made decades ago by the architects of the this hypothesis over the next several decades (Stutman,
cancer immunosurveillance hypothesis, Burnet and 1974, 1979), new studies in the 1990s—fueled by tech-
Thomas, that “there is little ground for optimism about nologic advances in mouse genetics and monoclonal
cancer” (Burnet, 1957) and “the greatest trouble with the antibody (mAb) production—reinvigorated and ulti-
idea of immunosurveillance is that it cannot be shown to mately validated the cancer immunosurveillance con-
exist in experimental animals” (Thomas, 1982), reflect cept (Smyth et al., 2001b; Dunn et al., 2002, 2004) and
the problems that, until recently, fomented intense de- expanded it to incorporate the contributions of both
bate over whether natural immune defense mechanisms innate and adaptive immunity.
can protect the host against the development of can- However, there has been a growing recognition that
cers of nonviral origin. The difficulty was clear: if im- immunosurveillance represents only one dimension of
munosurveillance of developing tumors in immunocom- the complex relationship between the immune system
petent hosts was indeed successful, then how could and cancer (Dunn et al., 2002, 2004; Schreiber et al.,
such an apparently invisible process be experimentally 2004). Recent work has shown that the immune system
revealed? With the development of mouse tumor models may also promote the emergence of primary tumors with
using inbred mice with molecularly defined immunodefi- reduced immunogenicity that are capable of escaping
ciencies, it has become possible to demonstrate the immune recognition and destruction (Shankaran et al.,
existence of a cancer immunosurveillance process that 2001). These findings prompted the development of the
can prevent primary tumor growth. Moreover, there is an cancer immunoediting hypothesis to more broadly en-
emerging recognition that cancer immunosurveillance compass the potential host-protective and tumor-sculpt-
represents only one step of a broader process, termed ing functions of the immune system throughout tumor
cancer immunoediting, that stresses the dual host-pro- development (Dunn et al., 2002, 2004). Cancer immuno-
editing is a dynamic process composed of three phases:
elimination, equilibrium, and escape (Figure 1). Elimina-*Correspondence: schreiber@immunology.wustl.edu
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Figure 1. The Three Phases of the Cancer Immunoediting Process
Normal cells (gray) subject to common oncogenic stimuli ultimately undergo transformation and become tumor cells (red) (top). Even at early
stages of tumorigenesis, these cells may express distinct tumor-specific markers and generate proinflammatory “danger” signals that initiate
the cancer immunoediting process (bottom). In the first phase of elimination, cells and molecules of innate and adaptive immunity, which
comprise the cancer immunosurveillance network, may eradicate the developing tumor and protect the host from tumor formation. However,
if this process is not successful, the tumor cells may enter the equilibrium phase where they may be either maintained chronically or
immunologically sculpted by immune “editors” to produce new populations of tumor variants. These variants may eventually evade the immune
system by a variety of mechanisms and become clinically detectable in the escape phase.
tion represents the classical concept of cancer immuno- sor and protects the immunocompetent host from the
development of neoplasia. In this section, we discusssurveillance, equilibrium is the period of immune-medi-
ated latency after incomplete tumor destruction in the current work on the elimination phase of the cancer
immunoediting process that specifically addresses theelimination phase, and escape refers to the final out-
growth of tumors that have outstripped immunological following three central questions. (1) What cells protect
the host from tumor development? (2) What are the criti-restraints of the equilibrium phase.
cal effector functions of the immune system in cancer
immunosurveillance? (3) How does the immune systemThe Elimination Phase: Assembling the Cancer
distinguish between a transformed cell and its normalImmunosurveillance Network
progenitor?Pivotal studies on IFN- (Dighe et al., 1994; Kaplan et
al., 1998; Shankaran et al., 2001; Street et al., 2001, 2002)
and perforin (van den Broek et al., 1996; Smyth et al., Adaptive and Innate Immune Cells Play Critical
Roles in Cancer Immunosurveillance2000a, 2000b; Street et al., 2001, 2002) have shown that
deficiencies in key immunologic molecules enhanced Rapidly accumulating data have begun to elucidate the
cellular basis of cancer immunosurveillance and demon-host susceptibility to both chemically induced and spon-
taneous tumors, demonstrating for the first time a critical strate that lymphocytes of both the adaptive and innate
immune compartments prevent tumor development.prediction of the prescient, but previously unsubstanti-
ated, cancer immunosurveillance hypothesis. Further- One of the most definitive studies performed to date
employed gene-targeted mice lacking the recombinasemore, other compelling data suggest that immunosur-
veillance is not restricted to mouse models but also activating gene (RAG)-2 (Shankaran et al., 2001) and
demonstrated that lymphocytes expressing rearrangedexists in humans (Dunn et al., 2002, 2004). Thus, today
the question is not if—but, rather, how—cancer immu- antigen receptors play critical roles in the cancer im-
munosurveillance process. Mice lacking RAG-2 (or itsnosurveillance functions as an extrinsic tumor suppres-
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obligate partner RAG-1) cannot somatically rearrange gression of developing papillomas to more aggressive
lymphocyte antigen receptors and therefore cannot pro- carcinomas. Together, these results reveal that  and
duce peripheral  T cells, B cells, NKT cells, or  T cell subsets make critical, but distinct, contributions
T cells (Shinkai et al., 1992). Since RAG-2 expression is to host antitumor defense mechanisms.
limited to cells of the lymphoid system, RAG-2/ mice NK and NKT cells also participate in cancer immuno-
provided an appropriate model to exclusively study the surveillance. C57BL/6 mice, depleted of both NK and
effects of host lymphocyte deficiency on tumor develop- NKT cells by using the anti-NK1.1 mAb, were two to
ment. Unlike other genetic models of immunodeficiency three times more susceptible to MCA-induced tumori-
(such as SCID mice), the absence of RAG-2 does not genesis than wild-type controls (Smyth et al., 2001a). A
affect DNA damage repair pathways in nonimmune cells similar effect was observed in C57BL/6 mice treated
undergoing transformation. Following subcutaneous in- with anti-asialo-GM1, which selectively depletes NK but
jection of the chemical carcinogen 3-methylcholan- not NKT cells. Although anti-asialo-GM1 can also de-
threne (MCA), 129/SvEv RAG-2/ mice developed sar- plete activated macrophages, the latter observation
comas at the injection site faster and with greater nevertheless supports the involvement of innate immune
frequency than strain-matched wild-type controls cells in blocking primary tumor development. NKT cells
(Shankaran et al., 2001). After 160 days, 30/52 RAG-2/ were also implicated in immunosurveillance by two
mice formed tumors, compared with 11/57 wild-type additional observations. First, J281/ mice, lacking
mice (p  0.0001). Similar findings were obtained in V14J281-expressing invariant NKT cells, developed
C57BL/6 RAG-1/ mice treated with MCA (Smyth et MCA-induced sarcomas at a higher frequency than wild-
al., 2001a). type controls (Smyth et al., 2000a). Second, mice treated
In addition, Helicobacter-negative RAG-2/ 129/ with the NKT cell-activating ligand -galactosylceramide
SvEv mice aged in a specific pathogen-free mouse facil- (-GalCer) throughout MCA-induced tumorigenesis ex-
ity and maintained on broad-spectrum antibiotics ad- hibited a reduced incidence of tumors and displayed a
ministered every other month developed significantly longer latency period to tumor formation than control
more spontaneous epithelial tumors than did wild-type mice (Hayakawa et al., 2003).
counterparts (Shankaran et al., 2001; A.T. Bruce and A recent provocative study by Cui et al. (Cui et al.,
R.D.S., unpublished data). Specifically, 31/32 RAG-2/ 2003) provides further evidence that innate immune cells
mice (13–28 months old) developed spontaneous neo- comprise an important arm of the immunosurveillance
plasia, predominantly of the intestine. Eight had prema- network. A single BALB/c mouse was serendipitously
lignant intestinal adenomas, 22 had intestinal adenocar- found that failed to form ascites when injected intraperi-
cinomas, and one had an intestinal adenoma and a lung toneally with the extremely aggressive S180 sarcoma
adenocarcinoma. In contrast, 21/33 wild-type mice re- cell line. Subsequent breeding revealed that the ob-
mained neoplasia free to the end of their lives. Of the served cancer resistance trait was germline transmissi-
wild-type mice that developed neoplastic disease, six had ble and was likely controlled by a single autosomal domi-
adenomas of the Harderian gland, lung, intestine, stom- nant locus. In addition, the resulting “spontaneous
ach, or liver, while six others developed unrelated can- regression/complete remission” (SR/CR) mice were able
cers that predominantly appeared late in life. Thus, lym- to kill a range of both syngeneic and allogeneic tumor
phocytes protect mice against both chemically-induced cells derived from multiple tissue sites. Despite their
and spontaneous tumor formation. avid antitumor resistance, SR/CR mice did not exhibit
Subsequent studies have extended these findings by autoimmune pathology or shortened lifespan. Interest-
identifying which of the possible RAG-dependent lym- ingly, resistance to S180 was also observed when the
phocyte subsets contribute to host antitumor defense. SR/CR trait was bred onto a nude genetic background,
This work highlighted roles for  T cells,  T cells, suggesting that the SR/CR phenotype is predominantly
and NKT cells in the immunosurveillance process. Mice
mediated by innate immune cells. Characterization of
lacking either  T cells (TCR / mice) or  T cells
the locus controlling the SR/CR phenotype should pro-
(TCR / mice) are more susceptible to MCA-induced
vide new insights into innate immune control of tumortumor formation than wild-type mice (on either an FVB
growth.or C57BL/6 genetic background) (Girardi et al., 2001;
Taken together, these data not only highlight roles forGao et al., 2003). In contrast, using a carcinogenesis
both innate and adaptive immune components in themodel involving initiation with 7, 12-dimethylbenz
elimination phase of cancer immunoediting but also[a]anthracene (DMBA) and promotion with 12-O-tetra-
underline the complexity of the host’s immune responsedecanoylphorbol 13-acetate (TPA), host protection
to developing tumors. Specifically, cancer immunosur-against tumor formation was found to be more depen-
veillance appears to be a multivariable process in whichdent on the action of  T cells than  T cells. Whereas
immunologic responses are influenced by a tumor’s cel-FVB strain TCR / mice formed significantly more
lular origin, mode of transformation, anatomic location,DMBA/TPA tumors than wild-type FVB controls, FVB
stromal response, cytokine production profile, and in-strain TCR / did not (Girardi et al., 2001, 2003). How-
herent immunogenicity. Thus, it remains critical toever, TCR /  / mice were significantly more sus-
assess the effects of a wide range of immunologicceptible to DMBA/TPA carcinogenesis than singly-defi-
components on tumor development in many differentcient TCR / mice (Girardi et al., 2003), revealing a
models—both chemically induced and spontaneous—host-protective role for  T cells in the setting of 
to determine whether the immunosurveillance of allT cell deficiency. Interestingly, in the same study TCR
cancer-susceptible tissues of the body is globally similar/ mice exhibited the highest ratio of carcinomas to
papillomas, suggesting that  T cells regulate the pro- or locally distinct.
Immunity
140
Effector Functions Underlying Immunosurveillance: IFN-	/	 and TCR / IFN-	/	mice, whereas the exper-
imental group consisted of lethally irradiated IFN-/IFN Production and Cytotoxicity
IFN Production mice reconstituted with a mixture of bone marrow from
TCR/  IFN-/ and TCR / IFN-	/	 mice. Thus,The studies that identified physiologically relevant cellu-
lar effectors of immunosurveillance have been comple- the only deficiency in the reconstituted experimental
group was that mature  T cells could not producemented by studies that defined two of the critical tasks
these immune cells must effect to eradicate developing IFN-. When challenged with MCA, the control bone
marrow chimera group displayed a susceptibility to tu-tumors: the production of IFN- and the ability to kill.
Endogenously produced interferon- (IFN-) was shown mor formation similar to that of wild-type mice. In con-
trast, chimeric mice with  T cells that could notto protect the host against the growth of transplanted
tumors and also the formation of primary chemically produce IFN- were significantly more susceptible to
MCA-induced tumor formation than wild-type counter-induced and spontaneous tumors (Dighe et al., 1994;
Kaplan et al., 1998; Shankaran et al., 2001; Street et al., parts and displayed an increased MCA susceptibility,
indistinguishable from that of IFN-/ mice. Thus, 2001, 2002). Injection of neutralizing mAbs for IFN- into
mice bearing transplanted, established Meth A tumors T cells are one physiologically relevant source of IFN-
in the cancer immunosurveillance process. Additionalblocked LPS-induced tumor rejection (Dighe et al.,
1994). In addition, transplanted fibrosarcomas grew work is required to identify if there are other cellular
sources of IFN- during tumor development and to de-faster and more efficiently in mice treated with IFN--
specific mAbs. In models of primary tumor formation, termine whether other IFN--producing cells participate
in responses to different types of tumors.IFN--insensitive 129/SvEv mice lacking either the
IFNGR1 ligand binding subunit of the IFN- receptor or More is known about the physiologically relevant tar-
gets of IFN-’s actions. Host cells are important targetsSTAT1, the transcription factor that mediates much of
IFN-’s biologic effects on cells (Bach et al., 1997), were of IFN- during development of protective antitumor
immune responses. STAT1/ mice with generalizedfound to be 10–20 times more sensitive than wild-type
mice to MCA tumor induction (Kaplan et al., 1998). These IFN-/IFN- insensitivity are more sensitive to MCA
primary tumor induction (Kaplan et al., 1998) and alsomice developed more tumors, more rapidly, and at lower
carcinogen doses than did wild-type controls. Similar cannot reject highly immunogenic transplanted IFN--
sensitive tumor cells (Fallarino and Gajewski, 1999; V.results were obtained in independent experiments by
using C57BL/6 mice lacking the gene encoding IFN- Shankaran and R.D.S., unpublished data). At least in
part, these results are explained by a requirement for(Street et al., 2001). In models of genetically driven tu-
morigenesis, mice lacking both the p53 tumor suppres- IFN- sensitivity at the level of the host immune compart-
ment. Through its capacity to promote the generationsor gene and either IFNGR1 or STAT1 formed a wider
tumor spectrum compared to IFN--sensitive mice lack- of tumor-specific CD4	 Th1 T cells and cytolytic T cells
(CTL) and to activate cytocidal activity in macrophages,ing p53 only (Kaplan et al., 1998). In another study, 16/
32 of IFN-/ C57BL/6 mice developed disseminated IFN- facilitates development of powerful anti-tumor ef-
fector functions mediated by both adaptive and innatelymphomas compared to 0/39 wild-type C57BL/6 mice
(Street et al., 2002). immunity (Bach et al., 1997). However, the tumor cells
themselves have also been shown to represent a criticalThe overlap between the IFN-- and lymphocyte-
dependent tumor suppressor pathways was revealed cellular target of IFN-. Highly immunogenic MCA-in-
duced tumor cells derived from IFN- sensitive RAG-by comparing tumor formation in 129/SvEv mice lacking
IFN- responsiveness (IFNGR1/ or STAT1/ mice), 2/ mice are rejected when injected into naive synge-
neic immunocompetent recipients (Shankaran et al.,lymphocytes (RAG-2/ mice), or both (RAG-2/ x
STAT1/) (RkSk mice) (Shankaran et al., 2001). Each 2001; G.P.D., C.M. Koebel, and R.D.S., unpublished
data). However, when the IFN- sensitivity of these cellsgroup of mice formed three times more chemically in-
duced tumors than syngeneic wild-type mice when in- is ablated by overexpression of a dominant-negative
IFNGR1 mutant, they become poorly immunogenic andjected with 100 
g of MCA. Since no significant differ-
ences were detected between any of the gene-targeted form aggressively growing tumors in wild-type mice
(Dighe et al., 1994; G.P.D., C.M. Koebel, and R.D.S.,mice, it was concluded that the IFN-/STAT1- and lym-
phocyte-dependent tumor suppressor mechanisms were unpublished data). Conversely, poorly immunogenic
MCA-sarcoma cells derived from IFNGR1/ mice be-largely overlapping. However, RkSk mice developed
spontaneous breast tumors that were not observed in come highly immunogenic cells and are rejected in im-
munocompetent mice after ectopic expression of wild-wild-type or RAG-2/ mice, therefore demonstrating
that the overlap between the two pathways was incom- type IFNGR1 and restoration of IFN- sensitivity (Kaplan
et al., 1998). IFNGR1/ tumor cells are also renderedplete.
Additional work has begun to identify the relevant highly immunogenic by ectopic expression of IFN--
inducible components of the MHC class I antigen pro-cellular sources and targets of IFN- in immunosurveil-
lance. Recent work suggests thatT cells are an impor- cessing and presentation pathway (Shankaran et al.,
2001; A.T. Bruce and R.D.S., unpublished data), thustant source of IFN- during the development of protec-
tive antitumor responses (Gao et al., 2003). To directly revealing that IFN-’s ability to upregulate tumor immu-
nogenicity is sufficient to explain the effects on tumortest if  T cells were a physiologically important source
of IFN- in blocking primary tumor formation, two sets detection and elimination in immunocompetent hosts.
One key remaining question is whether type I interfer-of bone marrow chimeras were generated. In the control
group, IFN-/ mice were lethally irradiated and recon- ons (IFN-/) also participate in cancer immunosurveil-
lance. Longstanding work from Gresser and colleaguesstituted with a mixture of bone marrow from TCR /
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has shown that in vivo neutralization of endogenously and CD8	  T cells recognize tumor antigens in the
context of MHC class II and class I proteins, respec-produced IFN-/ enhances growth of transplanted tu-
tively. Since the first human tumor antigen was identifiedmors in wild-type mice (Gresser and Belardelli, 2002).
in 1991 (van der Bruggen et al., 1991), many tumor anti-Moreover, administration of IFN-/ has positive thera-
gens have been cloned and can be segregated into fivepeutic actions on certain types of murine and human
categories: (1) differentiation antigens, e.g., melanocytecancers (Belardelli et al., 2002). More recent in vitro
differentiation antigens, Melan-A/MART-1, tyrosinase,work has pointed to a role for IFN-/ in preventing
and gp-100; (2) mutational antigens, e.g., abnormalcellular transformation through mechanisms involving
forms of p53; (3) overexpressed/amplified antigens, e.g.,enhanced cellular expression of the p53 tumor suppres-
HER-2/neu; (4) cancer-testis (CT) antigens, e.g., MAGEsor gene in cells exposed to type I IFN (Takaoka et
and NY-ESO-1; and (5) viral antigens, e.g., EBV and HPVal., 2003). Further work is needed to define the precise
(Boon and van der Bruggen, 1996; Rosenberg, 1999;cellular targets of IFN-/ in the cancer immunosur-
Old, 2003). The molecular definition of tumor antigensveillance process and to determine whether IFN-/
has revolutionized the field of tumor immunology byfunctions in a manner that is identical to or distinct
providing a firm basis for how the adaptive immunefrom IFN-.
system discriminates between normal and neoplasticCytolytic Capacity
cells.The second critical effector function of cancer immuno-
In addition to tumor antigens presented on MHC mole-surveillance is the immune system’s ability to kill tumor
cules, transformed cells may overexpress other mole-cells. Early studies identified perforin (pfp) as a critical
cular signposts that can function as recognition targetscytolytic molecule in the primary host antitumor re-
in the immunosurveillance process. Several studiessponse. After challenge with MCA, pfp/ mice formed
have pointed to the NKG2D-activating receptor, ex-two to three times more tumors than wild-type mice (van
pressed on NK cells,  T cells, and CD8  T cellsden Broek et al., 1996; Smyth et al., 2000a, 2000b; Street
(Bauer et al., 1999; reviewed in Raulet, 2003), as oneet al., 2001). In addition, 50% (10/20) of aging pfp/
important component that is used by both adaptive andC57BL/6 mice developed spontaneous disseminated
innate immune cells to distinguish cancer cells fromlymphomas as compared to 1/16 wild-type mice (Smyth
normal cells. Functional NKG2D receptors complexeset al., 2000b). The kinetics of lymphoma development
consist of the NKG2D ligand binding polypeptide andwere accelerated in pfp/ mice also lacking p53 (Smyth
either the DAP10 or DAP12 signaling polypeptide (Gilfil-et al., 2000b) or 2 microglobulin (Street et al., 2004).
lan et al., 2002). In humans, NKG2D binds to the MHCSubsequent studies revealed an important role for the
class I chain-related proteins A and B (MICA/B), as wellTNF-related apoptosis-inducing ligand (TRAIL) and have
as the UL16 binding proteins (ULBPs) (Cosman et al.,underscored the importance of cytotoxicity manifest by
2001; Pende et al., 2002) and the recently discoveredinnate immunity in immunosurveillance. A member of
lymphocyte effector cell toxicity-activating ligand (Letal)the TNF superfamily that induces apoptosis through en-
(Conejo-Garcia et al., 2003) (first reported as RAET1Egagement of the TRAIL-R2 (DR5) receptor in mice, TRAIL
[Radosavljevic et al., 2002] and also termed ULBP4is expressed constitutively on a subset of liver NK cells
[Chalupny et al., 2003]). The MICA/B proteins are highlyand is induced by either IFN- or IFN-/ in monocytes,
polymorphic, nonclassical MHC cell surface glycopro-NK cells, and dendritic cells (Smyth et al., 2003). When
teins that do not associate with 2m or require TAP1injected with low doses of MCA, C57BL/6 mice treated
for expression (Groh et al., 1996; Bahram, 2000). Inter-with neutralizing antibodies to TRAIL (Takeda et al.,
estingly, while MIC expression in normal tissues has only2002) or lacking the TRAIL gene (Cretney et al., 2002)
been documented on the gastrointestinal epithelium ofdeveloped fibrosarcomas at a higher incidence than
the stomach and large intestines, MICA/B proteins arewild-type controls. Moreover, p53	/ C57BL/6 mice
often expressed in primary carcinomas of the lung, kid-
treated with the neutralizing TRAIL-specific antibody de-
ney, prostate, ovary, colon (Groh et al., 1999) and liver
veloped more spontaneous sarcomas and disseminated
(Jinushi et al., 2003b), as well as in melanomas (Vetter
lymphomas over a two-year period than control IgG- et al., 2002). In addition, ULBPs (Pende et al., 2002) and
treated mice (Takeda et al., 2002). Further study is re- Letal (Conejo-Garcia et al., 2003) are also frequently
quired to identify the specific innate cell subsets that expressed on tumor cells. In mice, NKG2D binds to the
manifest the TRAIL-dependent antitumor effects. Con- retinoic acid early transcript 1 (Rae-1) family proteins
sidering that the TRAIL-R2 receptor is upregulated by Rae-1-, the minor histocompatibility antigen H60 (Die-
p53 in response to DNA damage (Wu et al., 1997, 1999), fenbach et al., 2000; Cerwenka et al., 2001), and mouse
TRAIL killing may be a critical link between target cell UL16 binding protein-like transcript (MULT-1) (Carayan-
genotoxic distress and immune-mediated destruction. nopoulos et al., 2002; Diefenbach et al., 2003). NKG2D
ligand expression has been observed on a wide range
Patrolling Transformation: Mechanisms that Adaptive of murine tumors (Diefenbach et al., 2000), and ectopic
versus Innate Immunity Use to Distinguish Tumor expression of Rae-1, H60, or MULT-1 was sufficient to
Cells from Normal Cells induce the rejection of several progressively growing,
The third central question concerns how cells of the transplantable tumors (Cerwenka et al., 2001; Diefen-
immunosurveillance network distinguish nascent trans- bach et al., 2001, 2003).
formed or established tumor cells from normal cells. It will be important to characterize the regulation of
Work over the last decade has begun to reveal the mo- NKG2D ligand expression in both human and murine
lecular basis of this crucial distinction particularly within cells. These molecules are often described as “stress
molecules,” but to date no cancer-relevant signalingthe adaptive immune compartment. Specifically, CD4	
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pathways have been causally linked to their expression. (Burnet, 1970). Moreover, the surveillance functions of
the immune system were thought to be executed onlyIn human cells, MICA/B gene expression has been in-
duced in several nontransformed human cell lines by at the earliest stages of tumorigenesis. However, recent
studies have started to explain what happens when tu-heat shock at 42C (Groh et al., 1999), infection with
human cytomegalovirus (Groh et al., 2001), or exposure mors develop in immunocompetent hosts, as they do
in individuals with cancer, and what has emerged fromto E. coli (Tieng et al., 2002), although in dendritic cells
MICA/B is upregulated by type I interferon (Jinushi et this is the realization that even when immunosurveil-
lance fails, the relationship between immunity and can-al., 2003a) or M. tuberculosis infection (Das et al., 2001).
However, it remains unclear how these conditions over- cer is far from over.
An appreciation of the complexity of the immune sys-lap the molecular cascades that underlie neoplastic
transformation (Hahn and Weinberg, 2002a; Hahn and tem/tumor interaction is based on work that compared
the immunogenicities of tumors derived from immuno-Weinberg, 2002b). In mice, Rae-1 is upregulated by reti-
noic acid in F9 cells (Nomura et al., 1994) and is also compromised versus immunocompetent mice. In one
study, 17/17 tumors derived from wild-type 129/SvEvexpressed early in development (Raulet, 2003). In addi-
tion, one study assessed the expression of the NKG2D mice and 20/20 tumors derived from immunodeficient
RAG-2/ mice grew progressively when transplantedligands H60 and Rae-1 after topical application of DMBA
and TPA (Girardi et al., 2001). While no expression of into RAG-2/ hosts (Shankaran et al., 2001). Further-
more, all 17 wild-type tumors grew progressively whenthese molecules was observed by RT-PCR in normal
skin, Rae-1 and H60 expression became detectable 24 transplanted into immunocompetent recipients. How-
ever, 8/20 tumors from RAG-2/ mice were rejectedhr after carcinogen treatment. Strikingly, expression of
both molecules was significantly increased in papillo- when transplanted into wild-type mice. These findings
showed that tumors formed in an immunodeficient envi-mas and carcinomas generated by DMBA/TPA treat-
ment. It is possible that the transformation process itself ronment are, as a group, more immunogenic than tu-
mors that develop in immunocompetent hosts. Similarly,induces molecules such as the NKG2D ligands so that
the genomic upheaval of tumorigenesis is directly trans- MCA-induced sarcomas derived from nude (Svane et
al., 1996) or SCID mice (Engel et al., 1996) were rejectedlated into enhanced immune recognition. Further study
on the immunology of transformation will be necessary more frequently than similar tumors derived from wild-
type mice when transplanted into wild-type hosts. More-to detail when—and how—in the course of tumorigene-
sis a cancer cell becomes immunogenic. over, sarcomas from J281/ mice grew progressively
when transplanted into J281/ recipients, but theirOne aspect of the cancer immunosurveillance pro-
cess that has been the subject of much controversy is growth was significantly impaired when transplanted
into wild-type mice (Smyth et al., 2000a). In addition,whether the unmanipulated immune system can detect a
developing tumor, even one that may express distinctive lymphomas from pfp/ mice grew avidly when trans-
planted into pfp/ recipients, but most were rejectedrecognition molecules on its surface or contain tumor-
specific antigens. In the past, it was argued that cellular when transplanted into wild-type mice (Street et al.,
2002).transformation did not provide a sufficient proinflamma-
tory or “danger” signal to alert the immune system to Together, the functional demonstration that immunity
shapes tumor immunogenicity has laid the foundationthe presence of a developing tumor (Matzinger, 1994;
Pardoll, 2003). However, it was recently realized that (1) for the development of the cancer immunoediting hy-
pothesis. This concept not only incorporates the originaldanger signals, such as uric acid (Shi et al., 2003), may
arise from the inherent biology of the tumor itself (Seong notion of cancer immunosurveillance but also recognizes
that even after escaping immunosurveillance, a tumor’sand Matzinger, 2004) and (2) induction of proinflamma-
tory responses through the generation of potential Toll- immunogenic phenotype is continuously shaped by the
immunological forces in its environment. In trying tolike receptor ligands, such as heat shock proteins
(Ohashi et al., 2000; Asea et al., 2002; Srivastava, 2002), understand how tumors may ultimately be sculpted by
immunity, we propose that a tumor that has breachedor extracellular matrix derivatives, such as hyaluronic
acid (Termeer et al., 2002) or heparan sulfates (John- the elimination phase of the immunoediting process may
experience two subsequent phases in its interactionsson et al., 2002), may share similarities to the events
that underlie activation of innate immune responses to with the host’s immune system: equilibrium, followed
by escape (Dunn et al., 2002, 2004).microbial pathogens (Janeway, 1989). Importantly,
whereas locally controlled inflammation may be involved
in initiating responses to tumors, excessive inflamma- The Equilibrium Phase of Cancer Immunoediting
tion may facilitate the transformation process (Balkwill Based on the experimental systems described above,
and Mantovani, 2001; Coussens and Werb, 2002; Dra- cancer immunosurveillance—i.e., the elimination phase
noff, 2004). It is therefore important to better define how of the cancer immunoediting process—can eradicate a
inflammation inhibits or promotes tumor development significant percentage of transformed cells. However,
in vivo. some tumor cells may withstand the formidable pres-
sure exerted by cancer immunosurveillance’s arsenal.
Therefore, we envision that there exists a period of la-Immunologic Sculpting of Cancer: When
Tumors Escape Immunosurveillance tency extending from the end of the elimination phase
to the beginning of the escape phase and the emergenceOriginally, cancer immunosurveillance was envisaged
as a binary process: the immune system either protected of clinically detectable malignant disease. This poten-
tially protracted period in the course of the immunethe host from the development or cancer, or it did not
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system/tumor interaction that probably occurs prior to Likewise, we envision three possible outcomes for a
the detection of clinically apparent tumors constitutes tumor that has entered the latent period of equilibrium:
the equilibrium phase. The events that occur in the equi- (1) eventual elimination by the immune system, (2) per-
librium phase of cancer immunoediting are likely quite manent maintenance in the equilibrium phase by the
similar to those previously envisaged to occur in a pro- cellular and molecular controls of immunity, or (3) es-
cess termed tumor dormancy (Wheelock et al., 1981; cape from immune pressure and transit to the final es-
Uhr et al., 1991). In both cases, while the immune system cape phase of the immunoediting process. Importantly,
initially constrains the growth of heterogeneous tumors the first two phases of the cancer immunoediting pro-
composed of unstable and rapidly mutating cells, it may cess represent potential goals for immunotherapy: tu-
approach an asymptote that Darwin could have pre- mor elimination or the durable control of cancer in equi-
dicted; although many of the original tumor cells are librium. Currently, the equilibrium phase is the most
destroyed, new variants arise carrying more mutations hypothetical of the three phases, and more data are
that provide them with increased resistance to immune needed to prove its existence. Thus, it is critical to estab-
attack. Ultimately, the dynamic interaction between im- lish new tumor models that will stringently test for the
munity and cancer in the equilibrium phase produces existence of the equilibrium phase during primary tumor
new populations of tumor cells vetted for survival in the development and subsequently define the effects of ex-
immunocompetent host. perimentally controlled variable periods of equilibrium
The tumor substrate on which immune cells continu- on the immunogenicities of established cancers in im-
ously act can contain cancer cells that harbor thousands munocompetent hosts.
of mutations (Loeb, 1991; Loeb et al., 2003). The enor-
mous plasticity of the cancer cell genome is thought to The Escape Phase of Cancer Immunoediting
arise from several types of genetic instability, including Edited tumor cells surviving the equilibrium phase of
nucleotide-excision repair instability, microsatellite in- the cancer immunoediting process enter the escape
stability, and chromosomal instability (Lengauer et al., phase where tumor growth proceeds unrestrained by
1998), the latter of which may induce gains or losses of immune pressure. To become clinically detectable in the
whole chromosomes. Thus, the tumor cell’s constant immunocompetent host, cancer cells must circumvent
genomic metamorphosis may eventually give rise to new both innate and adaptive immunologic defenses. The
phenotypes that display reduced immunogenicity. Im- degree to which a tumor’s immunogenicity is shaped
portantly, while the genesis of variation in tumor cell by its interaction with the host immune system may
immunogenicity may be stochastic, the tumor that ulti- be determined by the identities of the immune editors
mately emerges from the equilibrium phase is instruc- operative during the equilibrium phase. It is possible
tively shaped by the repertoire of immune “editors” in that tumor escape from each different tissue site of
its local environment and is thus conditioned to progress origin may be mechanistically distinct. It therefore fol-
into the escape phase of the immunoediting process. lows that metastatic lesions may experience the most
A clinical scenario that likely demonstrates the exis- significant immunologic sculpting—hewn by immune
tence of the equilibrium phase in humans is the transmis-
pressure from both primary tissue sites of origin as well
sion of cancer from organ transplant donors to recipi-
as distant sites of manifestation.
ents. In these situations, transplanted organs appear
Many studies have documented that tumor escape
grossly cancer free at harvest. While some organ donors
can be a direct consequence of alterations occurring inare subsequently found to harbor disease in other ana-
edited tumor targets themselves. For example, sometomic sites, other transplant donors either have no clini-
tumor cells develop direct or indirect lesions in antigencal history of cancer or have been in durable remission
processing and presentation pathways that facilitatefrom cancer prior to transplantation. One recent study
evasion from adaptive immune recognition. Analysis ofreported the occurrence of metastatic melanoma 1–2
human tumor specimens has shown that many displayyears posttransplant in two allograft recipients who had
losses of HLA class I proteins (Algarra et al., 2000; Marin-each received kidneys from the same donor (MacKie et
cola et al., 2000). In addition, other components of thisal., 2003). Upon subsequent investigation, it was found
pathway, including TAP1 and the immunoproteasomethat the donor had been treated for primary melanoma
subunits LMP2 and LMP7, are frequently deficient in16 years before her death, but was considered tumor
human tumors (Seliger et al., 2000). Moreover, otherfree at the time of organ donation. This study, together
lesions were identified that indirectly lead to antigenwith others in the literature (Penn, 1991, 1996; Elder et
processing or presentation defects. In one study, 4/17al., 1997; Suranyi et al., 1998), suggests that the pharma-
(25%) human lung adenocarcinoma cell lines were foundcologic suppression of the immune systems of these
to be unresponsive to IFN- due to the absence or ab-transplant recipients facilitated the rapid and progres-
normal function of components of the IFN- receptorsive outgrowth of occult tumors that were maintained
signaling pathway (Kaplan et al., 1998). Tumor cells ex-in the equilibrium phase by the donor’s intact immune
pressing these lesions failed to upregulate MHC class Isystem.
pathway activity when exposed to IFN-. Similar lesionsWe stress here that the cancer immunoediting pro-
were found in other studies that reported deficiencies ofcess may not always represent the linear progression
IFN receptor signaling pathway components in prostateof a tumor from the elimination phase through the equi-
cancer (G.P.D. and R.D.S., unpublished data) and mela-librium phase and into the final escape phase of clinical
noma (Wong et al., 1997).detection. Indeed, this process may be terminated in
Tumor escape has also been observed as one out-the elimination phase if the cancer immunosurveillance
process is successful at destroying a developing tumor. come of specific immunotherapeutic approaches. In one
Immunity
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study, ten patients harboring metastatic melanoma re- mice to reject tumors that grew progressively in con-
ceived adoptively transferred T cells specific to the tu- trol mice.
mor antigens MART-1/MelanA or gp100 with adjuvant These observations have stimulated interest in defin-
IL-2 therapy (Yee et al., 2002). Although 8/10 patients ing the tumor antigens recognized by Tregs and in de-
experienced stable, minor, or mixed clinical responses, termining whether an inhibitory T cell subset operates
3/5 patients studied exhibited specific loss of the tumor similarly in human cancer patients. By using SEREX
antigen that was targeted during treatment. Similar find- analysis (Sahin et al., 1995), an expression cloning tech-
ings were made in two other melanoma vaccine trials nique wherein IgG class antibodies present in the sera
in which multiple tumors from individual patients under- of tumor bearing hosts are used to identify tumor anti-
going vaccination with peptides from gp-100, MART-1, gens, a set of normal, nonmutated proteins, including
and tyrosinase lost expression of either the targeted Dna J-like 2, were identified as tumor antigens. When
melanoma antigens or all HLA molecules on which the challenged intravenously with fibrosarcoma cells, naive
antigens were presented (Jager et al., 1997; Khong et mice preimmunized with a subset of these SEREX-
al., 2004). These studies clearly show that tumors may defined antigens displayed a remarkable enhancement
evade both naturally occurring or therapeutically in- of pulmonary metastases compared to control mice
duced immune responses and suggest that at least (Nishikawa et al., 2003). This effect was inhibited if Dna
some of the dynamics underlying the cancer immuno- J-like 2-immunized mice were first depleted of CD25	
editing process in the unmanipulated host are also at cells. Moreover, permissiveness for tumor growth could
work when the three phases of cancer immunoediting be transferred to naive mice by passive transfer of
are initiated therapeutically. CD4	CD25	 T cells derived from Dna J-like 2-immu-
Other work has shown that inhibition of the protective nized hosts. More striking were the subsequent obser-
functions of the immune system may also facilitate tu- vations that (1) Dna J-like 2-immunized mice developed
mor escape. In this scenario, immunologically sculpted MCA-induced primary tumors more rapidly and with
tumor cell variants may overproduce immunosuppres- greater frequency compared to control mice and (2) this
sive cytokines, such as TGF- or IL-10 (Khong and effect was abrogated if the immunized mice were pre-
Restifo, 2002), or inhibit immune responses through treated with a depleting CD25-specific mAb (H. Nishi-
other mechanisms. One study documented that soluble kawa, T. Kato, L.J.O., and H. Shiku, unpublished data).
forms of the MIC NKG2D ligands, secreted by certain Together, these results suggest that CD4	CD25	 Tregs
human tumors, downregulated the NKG2D receptor on play an important role in suppressing protective immune
immune effector cells and attenuated lymphocyte-medi- responses against both primary and transplanted tumors.
ated cytotoxicity (Groh et al., 2002). Other studies dem- Recent studies have suggested that Tregs can also
onstrated that some tumor cells overproduce inhibitors be detected in a variety of human cancers. Specifically,
of T cell responses, such as galectin-1 (Rubinstein et individuals with nonsmall cell lung cancer or cancers of
al., 2004) and indoleamine 2,3-dioxygenase (IDO) (Uytten- the ovary (Woo et al., 2001), breast, or pancreas (Liya-
hove et al., 2003). Finally, other developing tumors sup- nage et al., 2002) all displayed elevated levels of
press induction of proinflammatory danger signals CD4	CD25	 Tregs. Moreover, another study has identi-
through mechanisms involving activated STAT3, leading fied the CT antigen LAGE-1 as the first human tumor
to impaired dendritic cell maturation that, in turn, pro- antigen specifically recognized by Tregs (Wang et al.,
vides the developing tumor with a potential mechanism 2004). These studies not only complement those in ani-
to escape immune detection (Wang et al., 2003). Thus, mal models but also point to the probable clinical rele-
a tumor may directly inhibit antitumor immune re- vance of regulatory T cell activity in human cancer. Fur-
sponses by multiple mechanisms. ther studies will be necessary to characterize the
Significant interest has recently focused on the phenotypes of Tregs, elucidate the molecular basis of
premise that tumors may also facilitate the generation,
their suppressive functions and identify more fully their
activation, or function of immunosuppressive T cell pop-
physiologic ligands.
ulations (Terabe and Berzofsky, 2004), such as IL-13-
producing NKT cells (Terabe et al., 2000) or CD4	CD25	
Conclusionregulatory T cells (T regs). The latter have attracted con-
In his writings about cancer immunosurveillance, Lewissiderable attention due to their involvement in control-
Thomas reflected that, “It seemed to me then, and stillling both pathologic and protective immune responses.
does, that some such built-in immunologic mechanismOriginally identified as a CD4	 T cell subset (comprising
ought to exist for natural defense against cancer”5%–10% of all peripheral T cells) constitutively express-
(Thomas, 1982). In this review, we have summarizeding CD25 that controls the behavior of autoreactive
the functional evidence showing that such immunologicT cells in vivo and suppresses T cell responses in vitro
defenses do, in fact, exist in the immunocompetent host(Sakaguchi et al., 1995; Read et al., 1998; Thornton and
and have discussed the nature of the known cellular andShevach, 1998), CD4	CD25	 Tregs were subsequently
molecular components that inhibit tumor development.suggested to play important roles in inhibiting naturally
Furthermore, we have pointed out several remainingoccurring and therapeutically induced protective im-
critical questions whose answers will ultimately framemune responses against tumors. Two studies showed
a full understanding of the host-protective cancer immu-that CD4	CD25	 Tregs are often responsible for the
nosurveillance network. We have also discussed thefailure of naive murine hosts to eliminate transplanted
studies demonstrating that cancer immunosurveillancetumors (Onizuka et al., 1999; Shimizu et al., 1999). Col-
is not the whole story, thus prompting the developmentlectively, these studies documented that depletion of
CD4	CD25	 Tregs by using an anti-CD25 mAb enabled of the cancer immunoediting hypothesis—i.e., the ac-
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Cerwenka, A., Baron, J.L., and Lanier, L.L. (2001). Ectopic expres-knowledgment that immunity’s powers to protect the
sion of retinoic acid early inducible-1 gene (RAE-1) permits naturalhost from cancer may also drive the generation of tu-
killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.mors better suited to survive in an immunologically in-
Proc. Natl. Acad. Sci. USA 98, 11521–11526.
tact environment. The most significant clinical implica-
Chalupny, J.N., Sutherland, C.L., Lawrence, W.A., Rein-Weston, A.,
tion of this hypothesis is that most, if not all, tumors that and Cosman, D. (2003). ULBP4 is a novel ligand for human NKG2D.
develop in humans may have undergone immunologic Biochem. Biophys. Res. Commun. 305, 129–135.
sculpting as a result of a cancer immunoediting process, Conejo-Garcia, J.R., Benencia, F., Courreges, M.C., Khang, E.,
with the most dramatic consequences of the process Zhang, L., Mohamed-Hadley, A., Vinocur, J.M., Buckanovich, R.J.,
probably occurring before the tumor is clinically detect- Thompson, C.B., Levine, B., and Coukos, G. (2003). Letal, A tumor-
associated NKG2D immunoreceptor ligand, induces activation andable. Ultimately, if the cancer immunoediting process
expansion of effector immune cells. Cancer Biol. Ther. 2, 446–451.indeed emerges as one of the leitmotifs of cancer pro-
Cosman, D., Mullberg, J., Sutherland, C.L., Chin, W., Armitage, R.,gression, then an improved understanding of the immu-
Fanslow, W., Kubin, M., and Chalupny, N.J. (2001). ULBPs, novelnobiology of cancer immunoediting and a molecular
MHC class I-related molecules, bind to CMV glycoprotein UL16 anddefinition of how tumors are shaped by this process
stimulate NK cytotoxicity through the NKG2D receptor. Immunity
will undoubtedly bring us closer to tumor immunology’s 14, 123–133.
capstone: the use of immunotherapy to control and/or Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer.
eradicate neoplastic disease in the human cancer pa- Nature 420, 860–867.
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Smyth, M.J. (2002). Increased susceptibility to tumor initiation and
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